# Mario E Lacouture

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 346 papers | 14,771 citations | 64 h-index | 112 g-index |
| 366 ext. papers | 17,759 ext. citations | 4.9 avg, IF | 6.64 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 346 | Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group **2017**, 5, 95 | | 999 |
| 345 | Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Annals of Oncology*, **2015**, 26, 2375-91 | 10.3 | 828 |
| 344 | Mechanisms of cutaneous toxicities to EGFR inhibitors. *Nature Reviews Cancer*, **2006**, 6, 803-12 | 31.3 | 555 |
| 343 | Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2010**, 28, 1351-7 | 2.2 | 347 |
| 342 | Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. *Supportive Care in Cancer*, **2011**, 19, 1079-95 | 3.9 | 306 |
| 341 | Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. *Oncologist*, **2007**, 12, 610-21 | 5.7 | 277 |
| 340 | Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. *Oncologist*, **2008**, 13, 1001-11 | 5.7 | 273 |
| 339 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discovery*, **2016**, 6, 154-65 | 24.4 | 269 |
| 338 | Management of Immunotherapy-Related Toxicities, Version 1.2019. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 255-289 | 7.3 | 246 |
| 337 | Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. *European Journal of Cancer*, **2016**, 60, 12-25 | 7.5 | 240 |
| 336 | Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. *New England Journal of Medicine*, **2015**, 373, 1733-47 | 59.2 | 215 |
| 335 | Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. *Cancer Immunology Research*, **2016**, 4, 383-9 | 12.5 | 199 |
| 334 | First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. *Cancer Discovery*, **2018**, 8, 184-195 | 24.4 | 198 |
| 333 | Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. *JAMA Oncology*, **2018**, 4, 384-388 | 13.4 | 191 |
| 332 | Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. *Clinical Cancer Research*, **2015**, 21, 1313-20 | 12.9 | 189 |
| 331 | Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. *Journal of the American Academy of Dermatology*, **2012**, 67, 1025-39 | 4.5 | 188 |
| 330 | Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. *Journal of Clinical Oncology*, **2012**, 30, 2375-83 | 2.2 | 175 |

| | | | |
|---|---|---|---|
| 329 | Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. *Annals of Oncology*, **2008**, 19, 1955-61 | 10.3 | 175 |
| 328 | Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. *Acta Oncologica*, **2008**, 47, 176-86 | 3.2 | 169 |
| 327 | Analysis of dermatologic events in vemurafenib-treated patients with melanoma. *Oncologist*, **2013**, 18, 314-22 | 5.7 | 162 |
| 326 | Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. *Cancer Immunology Research*, **2018**, 6, 1093-1099 | 12.5 | 161 |
| 325 | Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. *Supportive Care in Cancer*, **2013**, 21, 2933-48 | 3.9 | 146 |
| 324 | Ipilimumab in patients with cancer and the management of dermatologic adverse events. *Journal of the American Academy of Dermatology*, **2014**, 71, 161-9 | 4.5 | 142 |
| 323 | Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. *Oncology*, **2007**, 72, 152-9 | 3.6 | 141 |
| 322 | A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. *Supportive Care in Cancer*, **2010**, 18, 509-22 | 3.9 | 129 |
| 321 | Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. *Journal of the National Cancer Institute*, **2010**, 102, 47-53 | 9.7 | 127 |
| 320 | Efficacy of MEK inhibition in patients with histiocytic neoplasms. *Nature*, **2019**, 567, 521-524 | 50.4 | 126 |
| 319 | Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. *Cancer*, **2010**, 116, 3916-23 | 6.4 | 122 |
| 318 | Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. *Clinical Cancer Research*, **2011**, 17, 2997-3004 | 12.9 | 119 |
| 317 | Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 317, 596-605 | 27.4 | 116 |
| 316 | A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. *Clinical Cancer Research*, **2016**, 22, 5729-5737 | 12.9 | 109 |
| 315 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. *Clinical Cancer Research*, **2013**, 19, 2257-64 | 12.9 | 108 |
| 314 | Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. *European Journal of Cancer*, **2008**, 44, 781-90 | 7.5 | 108 |
| 313 | Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. *Journal of Clinical Oncology*, **2014**, 32, 3144-55 | 2.2 | 105 |
| 312 | Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. *American Journal of Clinical Dermatology*, **2013**, 14, 327-33 | 7.1 | 105 |

| | | | |
|---|---|---|---|
| 311 | Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails. *American Journal of Clinical Dermatology*, **2018**, 19, 31-39 | 7.1 | 104 |
| 310 | Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. *Cancer Discovery*, **2015**, 5, 64-71 | 24.4 | 101 |
| 309 | Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. *Lancet Oncology, The*, **2019**, 20, 1070-1082 | 21.7 | 101 |
| 308 | Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. *Current Oncology*, **2009**, 16, 16-26 | 2.8 | 101 |
| 307 | The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. *Journal of the American Academy of Dermatology*, **2013**, 69, e121-8 | 4.5 | 100 |
| 306 | Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. *Supportive Care in Cancer*, **2008**, 16, 557-66 | 3.9 | 94 |
| 305 | Dermatological adverse events with taxane chemotherapy. *European Journal of Dermatology*, **2016**, 26, 427-443 | 0.8 | 93 |
| 304 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 38-69 | 5.4 | 89 |
| 303 | NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2009**, 7 Suppl 1, S5-21; quiz S22-4 | 7.3 | 87 |
| 302 | Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. *Oncologist*, **2016**, 21, 1218-1229 | 5.7 | 86 |
| 301 | Treatment Outcomes of Immune-Related Cutaneous Adverse Events. *Journal of Clinical Oncology*, **2019**, 37, 2746-2758 | 2.2 | 84 |
| 300 | Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). *Oncologist*, **2009**, 14, 291-302 | 5.7 | 84 |
| 299 | Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor study. *Journal of Clinical Oncology*, **2012**, 30, 2466-74 | 2.2 | 82 |
| 298 | Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor by the monoclonal antibody fresolimumab (GC1008). *Cancer Immunology, Immunotherapy*, **2015**, 64, 437-46 | 7.4 | 79 |
| 297 | and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. *Cancer Discovery*, **2019**, 9, 199-209 | 24.4 | 79 |
| 296 | Immune checkpoint inhibitor-related dermatologic adverse events. *Journal of the American Academy of Dermatology*, **2020**, 83, 1255-1268 | 4.5 | 76 |
| 295 | Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. *Investigational New Drugs*, **2013**, 31, 1078-86 | 4.3 | 76 |
| 294 | Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. *Oncologist*, **2012**, 17, 135-44 | 5.7 | 74 |

| | | | |
|---|---|---|---|
| 293 | Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. *Annals of Oncology*, **2015**, 26, 2017-26 | 10.3 | 72 |
| 292 | Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. *Dermatologic Therapy*, **2011**, 24, 386-95 | 2.2 | 72 |
| 291 | A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. *Clinical Pharmacology and Therapeutics*, **2010**, 87, 303-10 | 6.1 | 72 |
| 290 | Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. *Clinical Genitourinary Cancer*, **2009**, 7, 11-9 | 3.3 | 72 |
| 289 | Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. *Oncology*, **2007**, 21, 34-6 | 1.8 | 72 |
| 288 | Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, **2013**, 69, 708-720 | 4.5 | 71 |
| 287 | Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. *Journal of Hepatology*, **2014**, 61, 309-17 | 13.4 | 71 |
| 286 | gp49B1-alpha(v)beta3 interaction inhibits antigen-induced mast cell activation. *Nature Immunology*, **2001**, 2, 436-42 | 19.1 | 71 |
| 285 | Analysis of dermatologic events in patients with cancer treated with lapatinib. *Breast Cancer Research and Treatment*, **2009**, 114, 485-93 | 4.4 | 70 |
| 284 | The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. *British Journal of Dermatology*, **2006**, 155, 852-4 | 4 | 70 |
| 283 | Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. *Cancer*, **2009**, 115, 1286-99 | 6.4 | 65 |
| 282 | Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). *Investigational New Drugs*, **2011**, 29, 1114-21 | 4.3 | 64 |
| 281 | Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. *Expert Review of Anticancer Therapy*, **2013**, 13, 721-8 | 3.5 | 63 |
| 280 | The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. *Journal of the American Academy of Dermatology*, **2011**, 65, 624-635 | 4.5 | 61 |
| 279 | Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. *British Journal of Dermatology*, **2017**, 176, 1649-1652 | 4 | 58 |
| 278 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events **2021**, 9, | | 58 |
| 277 | Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. *Seminars in Oncology*, **2014**, 41 Suppl 4, S1-14 | 5.5 | 55 |
| 276 | Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. *Clinical and Experimental Dermatology*, **2006**, 31, 783-5 | 1.8 | 55 |

| | | | |
|---|---|---|---|
| 275 | Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. *Nature Medicine*, **2019**, 25, 1839-1842 | 50.5 | 55 |
| 274 | Unanticipated toxicities from anticancer therapies: survivorsMperspectives. *Supportive Care in Cancer*, **2010**, 18, 1461-8 | 3.9 | 54 |
| 273 | Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. *Supportive Care in Cancer*, **2013**, 21, 1167-74 | 3.9 | 53 |
| 272 | Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. *Oncology*, **2009**, 77, 124-33 | 3.6 | 52 |
| 271 | The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. *The Journal of Supportive Oncology*, **2006**, 4, 236-8 | | 52 |
| 270 | Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. *American Journal of Clinical Dermatology*, **2018**, 19, 363-375 | 7.1 | 51 |
| 269 | Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?. *Journal of Clinical Oncology*, **2012**, 30, 329-30 | 2.2 | 50 |
| 268 | The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. *Journal of the American Academy of Dermatology*, **2012**, 67, 400-8 | 4.5 | 50 |
| 267 | Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. *Oncologist*, **2016**, 21, 1483-1491 | 5.7 | 50 |
| 266 | Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy. *JAMA Dermatology*, **2017**, 153, 694-697 | 5.1 | 49 |
| 265 | Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. *Nature Cancer*, **2020**, 1, 382-393 | 15.4 | 49 |
| 264 | The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. *Investigational New Drugs*, **2013**, 31, 787-97 | 4.3 | 49 |
| 263 | A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. *Oncologist*, **2015**, 20, 789-97 | 5.7 | 48 |
| 262 | An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. *Clinical Journal of Oncology Nursing*, **2008**, 12, 283-90 | 1.1 | 48 |
| 261 | Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. *Oncologist*, **2011**, 16, 1508-19 | 5.7 | 47 |
| 260 | Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. *Journal of the European Academy of Dermatology and Venereology*, **2017**, 31, e464-e469 | 4.6 | 46 |
| 259 | Life-threatening dermatologic adverse events in oncology. *Anti-Cancer Drugs*, **2014**, 25, 225-34 | 2.4 | 45 |
| 258 | Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. *International Journal of Dermatology*, **2011**, 50, 129-46 | 1.7 | 45 |

| | | | |
|---|---|---|---|
| 257 | Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. *American Journal of Surgical Pathology*, **2017**, 41, 1381-1389 | 6.7 | 44 |
| 256 | The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. *Investigational New Drugs*, **2012**, 30, 1773-81 | 4.3 | 44 |
| 255 | Hand-foot and stump syndrome to sorafenib. *Journal of Clinical Oncology*, **2007**, 25, 341-3 | 2.2 | 43 |
| 254 | Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. *British Journal of Dermatology*, **2006**, 154, 191-2 | 4 | 42 |
| 253 | Dermatological adverse events from BRAF inhibitors: a growing problem. *Current Oncology Reports*, **2013**, 15, 249-59 | 6.3 | 41 |
| 252 | Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1125-33 | 5.6 | 41 |
| 251 | Dermoscopic findings in cutaneous metastases. *JAMA Dermatology*, **2014**, 150, 429-33 | 5.1 | 40 |
| 250 | The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. *European Journal of Cancer*, **2012**, 48, 340-6 | 7.5 | 40 |
| 249 | Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. *Clinical Cancer Research*, **2010**, 16, 4452-60 | 12.9 | 40 |
| 248 | Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. *Photodermatology Photoimmunology and Photomedicine*, **2007**, 23, 42-5 | 2.4 | 40 |
| 247 | Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. *JAMA Dermatology*, **2018**, 154, 670-675 | 5.1 | 39 |
| 246 | Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, **2017**, 77, 902-910.e2 | 4.5 | 39 |
| 245 | Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. *Clinical Colorectal Cancer*, **2018**, 17, 85-96 | 3.8 | 38 |
| 244 | A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. *Annals of Oncology*, **2016**, 27, 1712-8 | 10.3 | 38 |
| 243 | The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. *Journal of the American Academy of Dermatology*, **2005**, 53, 291-302 | 4.5 | 38 |
| 242 | The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. *Journal of Drugs in Dermatology*, **2012**, 11, e61-5 | 2.2 | 38 |
| 241 | Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. *Dermatologic Therapy*, **2013**, 26, 135-48 | 2.2 | 37 |
| 240 | Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. *Archives of Dermatology*, **2011**, 147, 1403-9 | | 37 |

| | | | |
|---|---|---|---|
| 239 | Dermatologic toxicities of targeted anticancer therapies. *The Journal of Supportive Oncology*, **2010**, 8, 149-61 | | 37 |
| 238 | A comparison of type I collagen, fibronectin, and vitronectin in supporting adhesion of mechanically strained osteoblasts. *Journal of Bone and Mineral Research*, **2002**, 17, 481-92 | 6.3 | 36 |
| 237 | Alopecia with endocrine therapies in patients with cancer. *Oncologist*, **2013**, 18, 1126-34 | 5.7 | 35 |
| 236 | Hair disorders in cancer survivors. *Journal of the American Academy of Dermatology*, **2019**, 80, 1199-1213 | 4.5 | 35 |
| 235 | Xerosis and pruritus as major EGFRI-associated adverse events. *Supportive Care in Cancer*, **2016**, 24, 513-521 | 3.9 | 33 |
| 234 | Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. *Annals of Oncology*, **2012**, 23, 2103-2108 | 10.3 | 32 |
| 233 | The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). *Supportive Care in Cancer*, **2013**, 21, 1033-41 | 3.9 | 31 |
| 232 | Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. *Oncology*, **2007**, 21, 4-9 | 1.8 | 31 |
| 231 | Hair disorders in patients with cancer. *Journal of the American Academy of Dermatology*, **2019**, 80, 1179-1196 | 4.5 | 30 |
| 230 | Incidence and risk of xerosis with targeted anticancer therapies. *Journal of the American Academy of Dermatology*, **2015**, 72, 656-67 | 4.5 | 30 |
| 229 | Alopecia in patients treated with molecularly targeted anticancer therapies. *Annals of Oncology*, **2015**, 26, 2496-502 | 10.3 | 30 |
| 228 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. *Clinical Colorectal Cancer*, **2011**, 10, 333-9 | 3.8 | 30 |
| 227 | Immune checkpoint inhibitors to treat cutaneous malignancies. *Journal of the American Academy of Dermatology*, **2020**, 83, 1239-1253 | 4.5 | 30 |
| 226 | Single-agent dabrafenib for -mutated histiocytosis. *Haematologica*, **2018**, 103, e177-e180 | 6.6 | 29 |
| 225 | Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. *Journal of Molecular Diagnostics*, **2006**, 8, 604-12 | 5.1 | 29 |
| 224 | Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. *Thyroid*, **2014**, 24, 1329-40 | 6.2 | 28 |
| 223 | Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. *Supportive Care in Cancer*, **2017**, 25, 651-660 | 3.9 | 28 |
| 222 | The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. *British Journal of Dermatology*, **2015**, 173, 842-5 | 4 | 28 |

| | | | |
|---|---|---|---|
| 221 | Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. *Journal of the American Academy of Dermatology*, **2020**, 83, 1130-1143 | 4.5 | 27 |
| 220 | A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 325-333 | 4 | 27 |
| 219 | Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. *Clinical and Experimental Dermatology*, **2016**, 41, 8-15 | 1.8 | 27 |
| 218 | Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. *JAMA Dermatology*, **2019**, 155, 724-728 | 5.1 | 26 |
| 217 | Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study. *Oncologist*, **2019**, 24, 414-420 | 5.7 | 26 |
| 216 | Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. *European Journal of Haematology*, **2013**, 90, 142-50 | 3.8 | 26 |
| 215 | Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. *Cancer*, **2012**, 118, 5078-83 | 6.4 | 26 |
| 214 | Skin care management in cancer patients: an evaluation of quality of life and tolerability. *Supportive Care in Cancer*, **2011**, 19, 545-54 | 3.9 | 26 |
| 213 | Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. *Breast Cancer Research and Treatment*, **2012**, 132, 833-42 | 4.4 | 25 |
| 212 | Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. *Journal of Clinical Oncology*, **2014**, 32, e54-6 | 2.2 | 24 |
| 211 | Stoma care products represent a common and previously underreported source of peristomal contact dermatitis. *Contact Dermatitis*, **2017**, 76, 27-33 | 2.7 | 24 |
| 210 | Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. *Breast Cancer Research and Treatment*, **2012**, 135, 347-54 | 4.4 | 24 |
| 209 | Blackberry-induced hand-foot skin reaction to sunitinib. *Investigational New Drugs*, **2009**, 27, 389-90 | 4.3 | 24 |
| 208 | Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. *Cancer Investigation*, **2015**, 33, 70-7 | 2.1 | 23 |
| 207 | Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, 720-734 | 4.6 | 23 |
| 206 | Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. *Breast Cancer Research and Treatment*, **2014**, 146, 451-6 | 4.4 | 23 |
| 205 | Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 424-9 | 2 | 23 |
| 204 | Tracking of second primary melanomas in vemurafenib-treated patients. *JAMA Dermatology*, **2013**, 149, 488-90 | 5.1 | 23 |

| | | | |
|---|---|---|---|
| 203 | Skin toxicity of targeted cancer agents: mechanisms and intervention. *Future Oncology*, **2013**, 9, 1161-70 | 3.6 | 23 |
| 202 | Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. *Current Opinion in Oncology*, **2011**, 23, 343-51 | 4.2 | 23 |
| 201 | A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. *Supportive Care in Cancer*, **2015**, 23, 2231-44 | 3.9 | 22 |
| 200 | Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. *Oncologist*, **2020**, 25, 140-149 | 5.7 | 22 |
| 199 | Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. *Pediatric Blood and Cancer*, **2015**, 62, 798-806 | 3 | 22 |
| 198 | Temporal dependence of the effect of radiation on erlotinib-induced skin rash. *Journal of Clinical Oncology*, **2007**, 25, 2140; author reply 2141 | 2.2 | 22 |
| 197 | Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. *Annals of Oncology*, **2021**, 32, 157-170 | 10.3 | 22 |
| 196 | Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. *Breast Cancer Research and Treatment*, **2014**, 147, 631-8 | 4.4 | 21 |
| 195 | Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. *Community Oncology*, **2010**, 7, 23-29 | | 21 |
| 194 | Non-rash skin toxicities associated with novel targeted therapies. *Clinical Lung Cancer*, **2006**, 8 Suppl 1, S36-42 | 4.9 | 21 |
| 193 | Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. *Cancer Nursing*, **2007**, 30, S17-26 | 2.6 | 21 |
| 192 | p63 in Primary Cutaneous Carcinosarcoma. *American Journal of Dermatopathology*, **2007**, 29, 374-7 | 0.9 | 21 |
| 191 | Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics. *JAMA Dermatology*, **2019**, 155, 249-251 | 5.1 | 21 |
| 190 | Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2015**, 75, 747-55 | 3.5 | 20 |
| 189 | Characteristics of oral mucosal events related to bevacizumab treatment. *Oncologist*, **2012**, 17, 274-8 | 5.7 | 20 |
| 188 | Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. *Skin Therapy Letter*, **2007**, 12, 1-5 | 1.8 | 20 |
| 187 | Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists. *Clinical Genitourinary Cancer*, **2014**, 12, 341-7 | 3.3 | 19 |
| 186 | Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. *The Journal of Supportive Oncology*, **2009**, 7, 211-7 | | 19 |

| | | | |
|---|---|---|---|
| 185 | Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. *Cancer*, **2015**, 121, 60-8 | 6.4 | 18 |
| 184 | Nasal vestibulitis due to targeted therapies in cancer patients. *Supportive Care in Cancer*, **2015**, 23, 2391-8 | 3.9 | 18 |
| 183 | SJS/TEN 2019: From science to translation. *Journal of Dermatological Science*, **2020**, 98, 2-12 | 4.3 | 18 |
| 182 | Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. *Oncologist*, **2018**, 23, 891-899 | 5.7 | 18 |
| 181 | Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2014**, 37, 266-71 | 2.7 | 18 |
| 180 | Mechanisms of skin aging induced by EGFR inhibitors. *Supportive Care in Cancer*, **2016**, 24, 4241-8 | 3.9 | 17 |
| 179 | Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia. *Breast Cancer Research and Treatment*, **2016**, 157, 395-400 | 4.4 | 17 |
| 178 | The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. *Annals of Oncology*, **2011**, 22, 2366-2374 | 10.3 | 17 |
| 177 | Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. *Breast*, **2019**, 48, 89-97 | 3.6 | 16 |
| 176 | Clinical and dermoscopic features of combined cutaneous squamous cell carcinoma (SCC)/neuroendocrine [Merkel cell] carcinoma (MCC). *Journal of the American Academy of Dermatology*, **2015**, 73, 968-75 | 4.5 | 16 |
| 175 | Granuloma annulare associated with immune checkpoint inhibitors. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, e124-e126 | 4.6 | 16 |
| 174 | Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. *Journal of the American Academy of Dermatology*, **2018**, 78, 1102-1109 | 4.5 | 15 |
| 173 | Pruritus Associated with Targeted Anticancer Therapies and Their Management. *Dermatologic Clinics*, **2018**, 36, 315-324 | 4.2 | 15 |
| 172 | Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. *Supportive Care in Cancer*, **2013**, 21, 1919-26 | 3.9 | 15 |
| 171 | Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL). *Journal of Clinical Oncology*, **2008**, 26, 16122-16122 | 2.2 | 15 |
| 170 | Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. *Current Treatment Options in Oncology*, **2013**, 14, 389-404 | 5.4 | 14 |
| 169 | Eosinophilic rash secondary to temsirolimus. *Clinical Genitourinary Cancer*, **2009**, 7, E34-6 | 3.3 | 14 |
| 168 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. *Annals of Clinical and Translational Neurology*, **2020**, 7, 429-436 | 5.3 | 13 |

| | | | |
|---|---|---|---|
| 167 | Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200. *Annals of Oncology*, **2013**, 24, 2463-5 | 10.3 | 13 |
| 166 | Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. *Clinical Colorectal Cancer*, **2008**, 7, 309-14 | 3.8 | 13 |
| 165 | Safety of 5-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. *Breast Cancer Research and Treatment*, **2019**, 174, 15-26 | 4.4 | 13 |
| 164 | Dermatologic challenges in cancer patients and survivors. *Oncology*, **2007**, 21, 1462-72; discussion 1473, 1476, 1481 passim | 1.8 | 13 |
| 163 | The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review. *Breast Cancer Research and Treatment*, **2019**, 175, 267-276 | 4.4 | 12 |
| 162 | T-DM1-related telangiectasias: a potential role in secondary bleeding events. *Annals of Oncology*, **2015**, 26, 436-7 | 10.3 | 12 |
| 161 | Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. *Acta Dermato-Venereologica*, **2017**, 97, 539-540 | 2.2 | 12 |
| 160 | Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. *Pediatric Blood and Cancer*, **2018**, 65, e26699 | 3 | 12 |
| 159 | Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. *Clinical and Experimental Dermatology*, **2011**, 36, 733-8 | 1.8 | 12 |
| 158 | Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma. *Journal of the American Academy of Dermatology*, **2010**, 63, e58-9 | 4.5 | 12 |
| 157 | Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.. *Journal of Clinical Oncology*, **2011**, 29, 8520-8520 | 2.2 | 12 |
| 156 | Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. *Oncologist*, **2021**, 26, e316-e326 | 5.7 | 12 |
| 155 | A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. *Supportive Care in Cancer*, **2018**, 26, 1169-1179 | 3.9 | 12 |
| 154 | A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. *Journal of the American Academy of Dermatology*, **2017**, 77, 577-579 | 4.5 | 11 |
| 153 | Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. *British Journal of Haematology*, **2015**, 171, 84-90 | 4.5 | 11 |
| 152 | The role of inhibitors of the epidermal growth factor in management of head and neck cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 696-706 | 7.3 | 11 |
| 151 | First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. *Journal of Clinical Oncology*, **2017**, 35, 2508-2508 | 2.2 | 11 |
| 150 | A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. *Investigational New Drugs*, **2017**, 35, 742-750 | 4.3 | 10 |

| | | | |
|---|---|---|---|
| 149 | Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events. *Allergy: European Journal of Allergy and Clinical Immunology*, **2019**, 74, 2437-2448 | 9.3 | 10 |
| 148 | Management of dermatologic toxicities. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 686-9 | 7.3 | 10 |
| 147 | Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients. *American Journal of Dermatopathology*, **2015**, 37, 523-9 | 0.9 | 10 |
| 146 | Acneiform rash as a reaction to radiotherapy in a breast cancer patient. *The Journal of Supportive Oncology*, **2010**, 8, 268-71 | | 10 |
| 145 | Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. *Acta Oncologica*, **2015**, 54, 124-32 | 3.2 | 9 |
| 144 | Olmutinib-induced palmoplantar keratoderma. *British Journal of Dermatology*, **2018**, 178, e129-e131 | 4 | 9 |
| 143 | Diagnosis of blue nevus-like metastatic uveal melanoma confirmed by fluorescence in situ hybridization (FISH) for monosomy 3. *Journal of Cutaneous Pathology*, **2012**, 39, 621-5 | 1.7 | 9 |
| 142 | Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient. *Transplant Infectious Disease*, **2012**, 14, 410-4 | 2.7 | 9 |
| 141 | Dermatologic infections in cancer patients. *Cancer Treatment and Research*, **2014**, 161, 299-317 | 3.5 | 9 |
| 140 | Dermatologic issues in adult survivors of childhood cancer. *Journal of Cancer Survivorship*, **2009**, 3, 158-63 | 3.1 | 9 |
| 139 | Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. *Frontiers in Oncology*, **2020**, 10, 1045 | 5.3 | 9 |
| 138 | European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force Dermatology for cancer patients Position statement.. *Journal of the European Academy of Dermatology and Venereology*, **2021**, | 4.6 | 9 |
| 137 | Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia. *JAAD Case Reports*, **2017**, 3, 546-549 | 1.4 | 8 |
| 136 | PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.. *Journal of Clinical Oncology*, **2010**, 28, 8592-8592 | 2.2 | 8 |
| 135 | Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. *Journal of the European Academy of Dermatology and Venereology*, **2020**, 34, 1340-1347 | 4.6 | 8 |
| 134 | Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. *Cancer*, **2016**, 122, 1228-37 | 6.4 | 8 |
| 133 | Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. *Clinical Journal of Oncology Nursing*, **2018**, 22, 542-548 | 1.1 | 8 |
| 132 | Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, 485-500 | 7.1 | 7 |

| | | | |
|---|---|---|---|
| 131 | Dermatologic adverse events related to the PI3K□inhibitor alpelisib (BYL719) in patients with breast cancer. *Breast Cancer Research and Treatment*, **2020**, 183, 227-237 | 4.4 | 7 |
| 130 | A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia. *Investigational New Drugs*, **2019**, 37, 1247-1256 | 4.3 | 7 |
| 129 | Skinflammation and drug toxicity--a delicate balance. *Science Translational Medicine*, **2013**, 5, 199fs33 | 17.5 | 7 |
| 128 | Ossified soft tissue leiomyoma in a patient with sickle cell anemia. *Journal of Cutaneous Pathology*, **2005**, 32, 696-9 | 1.7 | 7 |
| 127 | Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic. *Journal of Clinical Oncology*, **2007**, 25, 9127-9127 | 2.2 | 7 |
| 126 | Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash. *Journal of Clinical Oncology*, **2008**, 26, 9559-9559 | 2.2 | 7 |
| 125 | Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). *Lung Cancer*, **2017**, 106, 76-82 | 5.9 | 6 |
| 124 | Treatment of multiple keratoacanthomas with erlotinib. *International Journal of Clinical Oncology*, **2010**, 15, 413-5 | 4.2 | 6 |
| 123 | Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). *Journal of Clinical Oncology*, **2009**, 27, CRA4027-CRA4027 | 2.2 | 6 |
| 122 | Restorative oncodermatology: Diagnosis and management of dermatologic sequelae from cancer therapies. *Journal of the American Academy of Dermatology*, **2021**, 85, 693-707 | 4.5 | 6 |
| 121 | Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. *Supportive Care in Cancer*, **2020**, 28, 6119-6128 | 3.9 | 6 |
| 120 | IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies. *Annals of Oncology*, **2021**, 32, 736-745 | 10.3 | 6 |
| 119 | Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. *Annals of Allergy, Asthma and Immunology*, **2021**, 126, 630-638 | 3.2 | 6 |
| 118 | Clinical management of EGFRI dermatologic toxicities: US perspective. *Oncology*, **2007**, 21, 17-21 | 1.8 | 6 |
| 117 | The growing importance of skin toxicity in EGFR inhibitor therapy. *Oncology*, **2009**, 23, 194, 196 | 1.8 | 6 |
| 116 | The microbial flora of taxane therapy-associated nail disease in cancer patients. *Journal of the American Academy of Dermatology*, **2018**, 78, 607-609 | 4.5 | 5 |
| 115 | Radiation Dermatitis: A Prevention Protocol for Patients With Breast Cancer. *Clinical Journal of Oncology Nursing*, **2018**, 22, 429-437 | 1.1 | 5 |
| 114 | Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma. *Journal of the American Academy of Dermatology*, **2011**, 65, 657-659 | 4.5 | 5 |

| | | | |
|---|---|---|---|
| 113 | Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. *Journal of Clinical Oncology*, **2011**, 29, e638-40 | 2.2 | 5 |
| 112 | Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. *JAMA Dermatology*, **2020**, 156, 963-972 | 5.1 | 5 |
| 111 | Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis. *Clinical Breast Cancer*, **2016**, 16, e69-74 | 3 | 5 |
| 110 | Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions. *Journal of the American Academy of Dermatology*, **2019**, 80, 608-616 | 4.5 | 4 |
| 109 | Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial. *BMJ Open*, **2020**, 10, e030114 | 3 | 4 |
| 108 | Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program. *Journal of the American Academy of Dermatology*, **2020**, 83, 955-957 | 4.5 | 4 |
| 107 | Skin necrosis induced by generic enoxaparin. *American Journal of Hematology*, **2013**, 88, 339 | 7.1 | 4 |
| 106 | Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch. *European Journal of Oncology Nursing*, **2013**, 17, 802-7 | 2.8 | 4 |
| 105 | Photodermatosis associated with eculizumab (Soliris): a novel monoclonal antibody directed against the complement protein C5. *American Journal of Hematology*, **2010**, 85, 392-3 | 7.1 | 4 |
| 104 | Clinical and histologic characterization of dermatologic adverse events from the pan-PI3K inhibitor buparlisib (BKM-120).. *Journal of Clinical Oncology*, **2014**, 32, e20639-e20639 | 2.2 | 4 |
| 103 | Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 237-243 | 7.3 | 4 |
| 102 | Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. *Journal of Thoracic Oncology*, **2021**, 16, 1759-1764 | 8.9 | 4 |
| 101 | EMPACT syndrome: limited evidence despite a high-risk cohort. *Journal of Neuro-Oncology*, **2014**, 119, 129-34 | 4.8 | 3 |
| 100 | Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. *BMC Cancer*, **2014**, 14, 5 | 4.8 | 3 |
| 99 | Effect of sunitinib on renal cell carcinoma cutaneous metastasis. *International Journal of Dermatology*, **2009**, 48, 1269-70 | 1.7 | 3 |
| 98 | Cutaneous toxicities of targeted cancer therapies. *Community Oncology*, **2008**, 5, 413-414 | | 3 |
| 97 | Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma. *Annals of Oncology*, **2007**, 18, 1744-5 | 10.3 | 3 |
| 96 | Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.. *Oncologist*, **2022**, 27, e223-e232 | 5.7 | 3 |

| | | | |
|---|---|---|---|
| 95 | Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. *Blood*, **2016**, 128, 480-480 | 2.2 | 3 |
| 94 | Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. *Journal of Clinical Oncology*, **2007**, 25, 19532-19532 | 2.2 | 3 |
| 93 | Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. *Journal of Clinical Oncology*, **2008**, 26, 19094-19094 | 2.2 | 3 |
| 92 | Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. *Journal of Clinical Oncology*, **2020**, 38, 11539-11539 | 2.2 | 3 |
| 91 | Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report. *Case Reports in Oncology*, **2021**, 14, 430-438 | 1 | 3 |
| 90 | Dermatologic infections in cancer patients treated with checkpoint inhibitors. *Journal of the American Academy of Dermatology*, **2021**, 85, 1528-1536 | 4.5 | 3 |
| 89 | Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy. *Cancer Discovery* , **2021**, 11, 2158-2167 | 24.4 | 3 |
| 88 | Incidence and risk of developing photosensitivity with targeted anticancer therapies. *Journal of the American Academy of Dermatology*, **2019**, 81, 1009-1011 | 4.5 | 2 |
| 87 | Drugs as a Frequent Cause of Acute Rash in Patients after CD34-Selected Peripheral Blood Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2172-2180 | 4.7 | 2 |
| 86 | Overview photography and short-term mole monitoring in patients taking a BRAF inhibitor. *JAMA Dermatology*, **2014**, 150, 1010-1 | 5.1 | 2 |
| 85 | In reply. *Oncologist*, **2013**, 18, e18 | 5.7 | 2 |
| 84 | Cutaneous and mucosal reactions to oncologic therapy. *Dermatologic Therapy*, **2011**, 24, 385 | 2.2 | 2 |
| 83 | Magnetic resonance imaging of paronychia induced by cetuximab. *Clinical and Experimental Dermatology*, **2009**, 34, e258-9 | 1.8 | 2 |
| 82 | The era of targeted therapies: increasing role for novel oncologic drugs in dermatology. *Archives of Dermatology*, **2007**, 143, 788-9 | | 2 |
| 81 | Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. *Journal of the Advanced Practitioner in Oncology*, **2017**, 8, 138-145 | 0.7 | 2 |
| 80 | Immune-related cutaneous adverse events due to checkpoint inhibitors. *Annals of Allergy, Asthma and Immunology*, **2021**, 126, 613-622 | 3.2 | 2 |
| 79 | reply to the letter to the editor Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial by Ceccarelli et al. *Annals of Oncology*, **2016**, 27, 2138-2139 | 10.3 | 2 |
| 78 | Dermatologic Adverse Events from Cancer Treatments **2019**, 131-173 | | 2 |

| | | | |
|---|---|---|---|
| 77 | Association of interleukin-6 and tumor necrosis factor- with mortality in hospitalized patients with cancer. *Journal of the American Academy of Dermatology*, **2021**, 84, 273-282 | 4.5 | 2 |
| 76 | A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia. *Breast Cancer Research and Treatment*, **2021**, 186, 107-114 | 4.4 | 2 |
| 75 | Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in V600E colorectal cancer. *JCO Precision Oncology*, **2018**, 2018, | 3.6 | 2 |
| 74 | Supportive Care in Patients Using Tumor Treating Fields Therapy **2016**, 103-116 | | 1 |
| 73 | A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. *Clinical Breast Cancer*, **2016**, 16, 87-94 | 3 | 1 |
| 72 | Antimicrotubule Agents **2013**, 208-214 | | 1 |
| 71 | Human papillomavirus-associated dysplastic condyloma of the tongue treated with Mohs micrographic surgery. *Dermatologic Surgery*, **2005**, 31, 477-9 | 1.7 | 1 |
| 70 | Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.. *PLoS ONE*, **2022**, 17, e0262151 | 3.7 | 1 |
| 69 | Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. *Blood*, **2013**, 122, 2876-2876 | 2.2 | 1 |
| 68 | A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA).. *Journal of Clinical Oncology*, **2017**, 35, e14064-e14064 | 2.2 | 1 |
| 67 | The CHANCE study: A prospective, longitudinal study of chemotherapy and hormonal therapy induced hair changes and alopecia, skin aging and nail changes in women with non-metastatic breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, e12500-e12500 | 2.2 | 1 |
| 66 | Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.. *Journal of Clinical Oncology*, **2018**, 36, e22093-e22093 | 2.2 | 1 |
| 65 | A multidisciplinary approach to optimizing care of patients treated with alpelisib.. *Breast*, **2021**, 61, 156-167 | 3.6 | 1 |
| 64 | Skin rash in a transplant patient receiving multiple drugs. *Cleveland Clinic Journal of Medicine*, **2003**, 70, 1071-5 | 2.8 | 1 |
| 63 | Dermatologic Adverse Events **2018**, 597-620 | | 1 |
| 62 | Gadolinium-associated nephrogenic systemic fibrosis. *Community Oncology*, **2008**, 5, 325-326 | | 1 |
| 61 | Management of Dermatologic Toxicities Associated With Targeted Therapy. *Journal of the Advanced Practitioner in Oncology*, **2016**, 7, 331-334 | 0.7 | 1 |
| 60 | Nail Abnormalities in Oncology Practice115-121 | | 1 |

| | | | |
|---|---|---|---|
| 59 | Oral Mucosal Complications of Cancer Therapy87-99 | | 1 |
| 58 | Psychosocial Issues in Oncology: Clinical Management of Psychosocial Distress, Health-Related Quality of Life, and Special Considerations in Dermatologic Oncology60-68 | | 1 |
| 57 | The microbial flora of clinically infected cutaneous metastases: a retrospective study. *Clinical and Experimental Dermatology*, **2020**, 45, 722-726 | 1.8 | 1 |
| 56 | Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. *Investigational New Drugs*, **2021**, 39, 785-795 | 4.3 | 1 |
| 55 | Management of Alopecia Due to Cancer Therapies **2018**, 621-631 | | 1 |
| 54 | Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience. *Urology*, **2018**, 119, 55-61 | 1.6 | 1 |
| 53 | Grading Dermatologic Adverse Events in Clinical Trials Using CTCAE v4.047-59 | | 1 |
| 52 | Dermatologic Toxicities **2010**, 361-380 | | 1 |
| 51 | Systemic anticancer agents **2013**, 397-407.e2 | | 1 |
| 50 | Differential radiation dermatitis in native skin and an autologous transplanted myocutaneous flap. *JAMA Dermatology*, **2014**, 150, 1365-7 | 5.1 | 0 |
| 49 | Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.. *Journal of Urology*, **2022**, 101097JU0000000000002425 | 2.5 | 0 |
| 48 | A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. *Journal of Patient-Reported Outcomes*, **2020**, 4, 54 | 2.6 | 0 |
| 47 | Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. *Supportive Care in Cancer*, **2021**, 29, 6253-6258 | 3.9 | 0 |
| 46 | Incidence of dermatologic adverse events in patients with cancer treated with concurrent immune checkpoint inhibitors and radiation therapy: A systematic review and meta-analysis. *Journal of the American Academy of Dermatology*, **2021**, 84, 871-875 | 4.5 | 0 |
| 45 | Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors. *Journal of the American Podiatric Medical Association*, **2018**, 108, 508-516 | 1 | 0 |
| 44 | Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.. *Critical Reviews in Oncology/Hematology*, **2022**, 174, 103696 | 7 | 0 |
| 43 | Cutaneous Adverse Events of Systemic Melanoma Treatments **2019**, 1-29 | | |
| 42 | Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". *Journal of the American Academy of Dermatology*, **2015**, 73, e35-6 | 4.5 | |

| | | |
|---|---|---|
| 41 | Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer. *JAMA Dermatology*, **2016**, 152, 1054-5 | 5.1 |
| 40 | Cutaneous Adverse Events of Systemic Melanoma Treatments **2019**, 743-771 | |
| 39 | Dermatitis and Alopecia **2013**, 147-166 | |
| 38 | Small Molecule Multikinase Inhibitors **2013**, 196-207 | |
| 37 | Alkylating Agents **2013**, 145-159 | |
| 36 | Topoisomerase-Interacting Agents **2013**, 170-183 | |
| 35 | Radiation-Induced Skin Reactions **2013**, 264-280 | |
| 34 | Types of Dermatologic Reactions **2013**, 33-46 | |
| 33 | Paraneoplastic, Inherited Cancer Syndrome, and Environmental Carcinogen-Related Dermatoses **2013**, 75-85 | |
| 32 | Topical Anticancer Therapies **2013**, 301-309 | |
| 31 | Extravasation Reactions **2013**, 295-300 | |
| 30 | Structure and Function of the Integumentary System and the Dermatology Lexicon **2013**, 24-32 | |
| 29 | Management of treatment-related dermatologic adverse effects **2011**, 115-120 | |
| 28 | Reply to M. Rother. *Journal of Clinical Oncology*, **2010**, 28, e475-e476 | 2.2 |
| 27 | HSHV/HHV8-Associated Primary Cutaneous Plasmablastic Lymphoma in a Patient with Castleman Disease and Kaposi Sarcoma. *Journal of Cutaneous Pathology*, **2008**, 33, 67-67 | 1.7 |
| 26 | Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease. *Blood*, **2021**, 138, 3915-3915 | 2.2 |
| 25 | Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I): An ACCRU trial.. *Journal of Clinical Oncology*, **2018**, 36, e22075-e22075 | 2.2 |
| 24 | Dermatologic Cancer Pain Syndromes **2019**, 133-138 | |

| | | |
|---|---|---|
| 23 | Dermatological Complications of Systemic Therapies for Melanoma **2019**, 1-22 | |
| 22 | Dermatological Complications of Systemic Therapies for Melanoma **2020**, 1337-1358 | |
| 21 | Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia. *Blood*, **2014**, 124, 24-24 | 2.2 |
| 20 | Unraveling the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms through Whole Exome Sequencing. *Blood*, **2014**, 124, 1887-1887 | 2.2 |
| 19 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Blood*, **2015**, 126, 481-481 | 2.2 |
| 18 | Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies **2011**, 379-385 | |
| 17 | Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis. *Blood*, **2011**, 118, 5120-5120 | 2.2 |
| 16 | Hair Disorders Associated with Anticancer Agents100-114 | |
| 15 | Management Options for Hot Flashes in Cancer Patients131-143 | |
| 14 | Antimetabolite Reactions160-169 | |
| 13 | Agents for the Management of Hematologic Reactions257-263 | |
| 12 | Appearance-Related Concerns in the Cancer Patient410-415 | |
| 11 | Histone Deacetylase Inhibitors, Proteasome Inhibitors, Demethylating Agents, Arsenicals, and Retinoids215-223 | |
| 10 | Hematopoietic Stem Cell Transplantation and Graft Versus Host Disease281-294 | |
| 9 | Dermatologic Techniques and Procedures401-409 | |
| 8 | Dermatologic Therapeutics and Formulations384-400 | |
| 7 | Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. *Blood*, **2013**, 122, 5274-5274 | 2.2 |
| 6 | Late Dermatologic Conditions337-364 | |

| | | |
|---|---|---|
| 5 | Life-threatening (Serious) Dermatologic Adverse Events310-318 | |
| 4 | Vulvar lichen sclerosus in the setting of cancer treatment A case series and review of the literature. *International Journal of Womenls Dermatology*, **2020**, 6, 220 | 2 |
| 3 | Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. *Oncologist*, **2021**, 26, 610-618 | 5.7 |
| 2 | Anticancer Therapies **2018**, 604-616 | |
| 1 | Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.. *Breast Cancer Research and Treatment*, **2022**, 1 | 4.4 |